Brandon W Higgs

Summary

Affiliation: MedImmune Vaccines
Country: USA

Publications

  1. pmc A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients
    Brandon W Higgs
    MedImmune, LLC, Gaithersburg, Maryland, USA
    Ann Rheum Dis 73:256-62. 2014
  2. doi request reprint Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway
    Brandon W Higgs
    Translational Sciences, MedImmune, One MedImmune Way, Gaithersburg, MD 20878, USA
    Ann Rheum Dis 70:2029-36. 2011
  3. ncbi request reprint Inhibition of myogenic microRNAs 1, 133, and 206 by inflammatory cytokines links inflammation and muscle degeneration in adult inflammatory myopathies
    Robert W Georgantas
    MedImmune, LLC, Gaithersburg, Maryland
    Arthritis Rheumatol 66:1022-33. 2014
  4. pmc Genomic signatures characterize leukocyte infiltration in myositis muscles
    Wei Zhu
    Translational Sciences, MedImmune, LLC, Gaithersburg, MD 20878, USA
    BMC Med Genomics 5:53. 2012
  5. doi request reprint Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients
    Brandon W Higgs
    Translational Sciences, MedImmune, LLC, Gaithersburg, MD 20878, USA
    Int J Rheum Dis 15:25-35. 2012
  6. doi request reprint Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus
    Yihong Yao
    MedImmune, Gaithersburg, Maryland 20878, USA
    Arthritis Rheum 60:1785-96. 2009
  7. pmc Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus
    Yihong Yao
    MedImmune, Translational Sciences, One MedImmune Way, Gaithersburg, MD 20878, USA
    Arthritis Res Ther 12:S6. 2010
  8. pmc Suppression of soluble T cell-associated proteins by an anti-interferon-α monoclonal antibody in adult patients with dermatomyositis or polymyositis
    Xiang Guo
    MedImmune, One MedImmune Way, Gaithersburg, MD 20878, USA
    Rheumatology (Oxford) 53:686-95. 2014
  9. ncbi request reprint MicroRNA-206 induces G1 arrest in melanoma by inhibition of CDK4 and Cyclin D
    Robert W Georgantas
    MedImmune, LLC, Gaithersburg, MD, USA
    Pigment Cell Melanoma Res 27:275-86. 2014
  10. pmc Altered expression of insulin receptor isoforms in breast cancer
    Jiaqi Huang
    MedImmune, LLC, Gaithersburg, Maryland, United States of America
    PLoS ONE 6:e26177. 2011

Collaborators

Detail Information

Publications15

  1. pmc A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients
    Brandon W Higgs
    MedImmune, LLC, Gaithersburg, Maryland, USA
    Ann Rheum Dis 73:256-62. 2014
    ....
  2. doi request reprint Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway
    Brandon W Higgs
    Translational Sciences, MedImmune, One MedImmune Way, Gaithersburg, MD 20878, USA
    Ann Rheum Dis 70:2029-36. 2011
    ....
  3. ncbi request reprint Inhibition of myogenic microRNAs 1, 133, and 206 by inflammatory cytokines links inflammation and muscle degeneration in adult inflammatory myopathies
    Robert W Georgantas
    MedImmune, LLC, Gaithersburg, Maryland
    Arthritis Rheumatol 66:1022-33. 2014
    ..The purpose of this study was to identify possible new targets for drug development by exploring the mechanism by which inflammation may play a role in the pathology of the inflammatory myopathies...
  4. pmc Genomic signatures characterize leukocyte infiltration in myositis muscles
    Wei Zhu
    Translational Sciences, MedImmune, LLC, Gaithersburg, MD 20878, USA
    BMC Med Genomics 5:53. 2012
    ....
  5. doi request reprint Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients
    Brandon W Higgs
    Translational Sciences, MedImmune, LLC, Gaithersburg, MD 20878, USA
    Int J Rheum Dis 15:25-35. 2012
    ....
  6. doi request reprint Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus
    Yihong Yao
    MedImmune, Gaithersburg, Maryland 20878, USA
    Arthritis Rheum 60:1785-96. 2009
    ..e., granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-10 (IL-10), tumor necrosis factor alpha (TNFalpha), and IL-1beta, in SLE...
  7. pmc Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus
    Yihong Yao
    MedImmune, Translational Sciences, One MedImmune Way, Gaithersburg, MD 20878, USA
    Arthritis Res Ther 12:S6. 2010
    ....
  8. pmc Suppression of soluble T cell-associated proteins by an anti-interferon-α monoclonal antibody in adult patients with dermatomyositis or polymyositis
    Xiang Guo
    MedImmune, One MedImmune Way, Gaithersburg, MD 20878, USA
    Rheumatology (Oxford) 53:686-95. 2014
    ..The aim of this study was to identify serum markers that are modulated by an investigational anti-IFN-α mAb, sifalimumab, in adult DM or PM patients...
  9. ncbi request reprint MicroRNA-206 induces G1 arrest in melanoma by inhibition of CDK4 and Cyclin D
    Robert W Georgantas
    MedImmune, LLC, Gaithersburg, MD, USA
    Pigment Cell Melanoma Res 27:275-86. 2014
    ..Additionally, hsa-miR-206 transfection induced G1 arrest in multiple melanoma cell lines. These observations support hsa-miR-206 as a tumor suppressor in melanoma and identify Cyclin C, Cyclin D1, and CDK4 as miR-206 targets...
  10. pmc Altered expression of insulin receptor isoforms in breast cancer
    Jiaqi Huang
    MedImmune, LLC, Gaithersburg, Maryland, United States of America
    PLoS ONE 6:e26177. 2011
    ....
  11. doi request reprint A whole genome transcriptional analysis of the early immune response induced by live attenuated and inactivated influenza vaccines in young children
    Wei Zhu
    MedImmune, Translational Sciences, Gaithersburg, MD 20878, USA
    Vaccine 28:2865-76. 2010
    ....
  12. pmc Type I interferon: potential therapeutic target for psoriasis?
    Yihong Yao
    MedImmune, Inc, Gaithersburg, Maryland, United States of America
    PLoS ONE 3:e2737. 2008
    ..To better understand the pathogenesis of this disease and identify potential mediators, we used whole genome array analysis to profile paired lesional and nonlesional psoriatic skin and skin from healthy donors...
  13. pmc Increased IR-A/IR-B ratio in non-small cell lung cancers associates with lower epithelial-mesenchymal transition signature and longer survival in squamous cell lung carcinoma
    Liyan Jiang
    MedImmune Inc, LLC, One MedImmune Way, 20878 Gaithersburg, MD, USA
    BMC Cancer 14:131. 2014
    ..To evaluate the insulin receptor isoform mRNA expression status in non-small cell lung cancer (NSCLC) patients...
  14. doi request reprint The plasma cell signature in autoimmune disease
    Katie Streicher
    MedImmune, Gaithersburg, Maryland
    Arthritis Rheumatol 66:173-84. 2014
    ..We undertook this study to investigate the prevalence of PCs and their relationship to known pathogenic pathways to increase our understanding of the role of PCs in disease progression and treatment response...
  15. pmc Gene expression and genetic variation data implicate PCLO in bipolar disorder
    Kwang H Choi
    Stanley Laboratory of Brain Research, Rockville, Maryland, USA
    Biol Psychiatry 69:353-9. 2011
    ..We then tested these SNPs for association with bipolar disorder in large case-control samples...